BNP PARIBAS FINANCIAL MARKETS - UROGEN PHARMA LTD ownership

UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 80 filers reported holding UROGEN PHARMA LTD in Q3 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of UROGEN PHARMA LTD
ValueSharesWeighting
Q3 2023$229,470
+334.6%
16,379
+221.0%
0.00%
Q2 2023$52,806
+3129.7%
5,102
+2782.5%
0.00%
Q1 2023$1,635
-85.6%
177
-86.2%
0.00%
Q4 2022$11,362
-99.9%
1,281
-3.8%
0.00%
Q3 2022$11,074,000
-82.2%
1,331
-82.4%
0.00%
Q2 2022$62,080,000
+319.5%
7,580
+346.1%
0.00%
Q1 2022$14,798,000
-65.4%
1,699
-62.2%
0.00%
Q4 2021$42,728,000
-28.6%
4,493
+26.2%
0.00%
Q3 2021$59,862,000
+406.5%
3,559
+359.8%
0.00%
Q2 2021$11,819,000
-86.3%
774
-82.6%
0.00%
Q1 2021$86,472,000
+26.9%
4,439
+17.4%
0.00%
Q4 2020$68,152,000
-23.0%
3,782
-17.6%
0.00%
Q3 2020$88,503,000
+217.6%
4,588
+330.0%
0.00%
Q2 2020$27,870,000
-74.4%
1,067
-82.5%
0.00%
Q1 2020$108,788,000
+30.8%
6,098
+144.6%
0.00%
Q4 2019$83,191,000
+3.9%
2,493
-25.8%
0.00%
Q3 2019$80,045,0003,3590.00%
Other shareholders
UROGEN PHARMA LTD shareholders Q3 2020
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 2,620,545$36,713,8356.69%
Wildcat Capital Management, LLC 495,606$6,943,4402.79%
SILVERARC CAPITAL MANAGEMENT, LLC 508,883$7,129,4512.16%
Opaleye Management Inc. 320,000$4,483,2001.46%
AlphaCentric Advisors LLC 165,000$2,311,6501.31%
Soleus Capital Management, L.P. 372,000$5,211,7200.48%
EAM Investors, LLC 170,523$2,389,0270.46%
RA Capital Management 1,483,697$20,786,5950.41%
Parkman Healthcare Partners LLC 145,311$2,035,8070.37%
MENORA MIVTACHIM HOLDINGS LTD. 2,303,031$32,265,4640.29%
View complete list of UROGEN PHARMA LTD shareholders